Ibuprofen Kabi (Ibuprofen)

Ibuprofen inhibits both COX‑1 and COX‑2 enzymes, reducing the synthesis of prostaglandins that mediate inflammation, pain signaling, and fever generation. Lower prostaglandin levels result in decreased peripheral sensitization and a reset of the hypothalamic temperature set‑point.

The specific dose and infusion rate of Ibuprofen Kabi are determined by the prescribing clinician based on the patient’s age, weight, clinical condition and renal function. Healthcare professionals should follow local prescribing guidelines and product labeling.

Safety data for intravenous ibuprofen in pregnancy are limited, and the drug is generally avoided unless clearly needed. Breastfeeding mothers should consult a healthcare provider, as ibuprofen can be excreted in milk and may affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and necessary import documentation.

Ibuprofen Kabi offers a well‑characterized safety profile and is non‑selective for COX‑1/COX‑2, similar to other IV NSAIDs such as ketorolac. Compared with ketorolac, ibuprofen may have a slightly lower risk of renal adverse effects but shares common gastrointestinal and bleeding risks. Choice depends on clinical judgment, dosing convenience and patient‑specific factors.

Ibuprofen Kabi must be stored refrigerated at 2‑8 °C. The solution should be kept in its original container, protected from light, and must not be frozen or shaken. Once removed from refrigeration, it should be used within the time frame indicated on the label.

The product is supplied as a sterile intravenous solution. It is administered by slow infusion through a suitable IV line, usually over 15‑30 minutes, under the supervision of qualified medical personnel. Infusion rate and total dose are set by the prescriber.

Serious risks include gastrointestinal bleeding or ulceration, acute kidney injury, severe hypersensitivity reactions such as anaphylaxis, and cardiovascular events like myocardial infarction or stroke, especially with high‑dose or prolonged therapy. Prompt medical attention is required if any of these occur.

Ibuprofen Kabi is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, active gastrointestinal bleeding, severe renal or hepatic impairment, and in those with established cardiovascular disease where NSAID use is discouraged. Clinicians should also avoid use in patients receiving anticoagulants without careful monitoring.